{"prompt": "['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', '6.11', 'Discontinuation of Study Treatment', '81', '6.11.1 Temporary Discontinuation of Study Treatment', '81', '6.11.2', 'Permanent Discontinuation of Study Treatment', '82', '6.12', 'Blinding', '84', '6.13', 'Prior and Concomitant Treatments', '84', '6.13.1', 'Olokizumab Potential Impact on Cytochrome P and', 'Transporter Pathways', '86', '6.13.2', 'Allowed Medications', '87', '6.13.3', 'Modification of Background Therapy', '88', '6.14', 'Medical Treatment for Subjects after End of Treatment', 'Period', '89', '7.', 'EFFICACY, SAFETY, PHARMACOKINETIC, AND HEALTH', 'OUTCOME ASSESSMENTS', '90', '7.1', 'Efficacy Assessments', '90', '7.1.1', 'American College of Rheumatology 20%/50%/70%', 'Response Criteria', '90', '7.1.2', '66-68 Joint Assessment', '90', '7.1.3', 'Patient Global Assessment of Disease Activity (Visual', 'Analog Scale)', '91', '7.1.4', 'Patient Assessment of Pain (Visual Analog Scale)', '91', '7.1.5', 'Physician Global Assessment (Visual Analog Scale)', '91', '7.1.6', 'Disease Activity Score 28-Joint Count (C-Reactive', 'Protein)', '91', '7.1.7', 'Disease Activity Score 28-Joint Count (Erythrocyte', 'Sedimentation Rate)', '92', '7.1.8', 'Simplified Disease Activity Index', '92', '7.1.9', 'Clinical Disease Activity Index', '92', '7.1.10', 'Health Assessments and Patient-Reported Outcomes', '93', '7.1.10.1', 'Health Assessment Questionnaire - Disability', 'Index', '93', '7.1.10.2', 'Short Form-36', '93', '7.1.10.3', 'European Quality of Life - 5 Dimensions', '94', '7.1.10.4', 'Work Productivity Survey - Rheumatoid', 'Arthritis', '95', '7.1.10.5', 'Functional Assessment of Chronic Illness', 'Therapy - Fatigue Scale', '95', '7.2', 'Pharmacokinetics', '95', '7.3', 'Immunogenicity', '96', '7.4', 'Safety', '96', '7.4.1', 'Adverse Events', '97', '7.4.1.1', 'Eliciting Adverse Event Information', '99', '7.4.2', 'Serious Adverse Events', '99', 'Amendment 2: 06 March 2019', '13', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', '7.4.2.1', 'Lack of Efficacy or Worsening of', 'Rheumatoid Arthritis', '101', '7.4.2.2', 'Overdose', '101', '7.4.2.3', 'Reporting and Follow-up Requirements for', 'Pregnancies', '102', '7.4.3', 'Adverse Events of Special Interest', '103', '7.4.3.1', 'Infections', '104', '7.4.3.2', 'Systemic Injection Reactions, Including', 'Anaphylaxis', '104', '7.4.3.3', 'Gastrointestinal Perforation', '105', '7.4.3.4', 'Hepatotoxicity', '106', '7.4.3.5', 'Injection Site Reactions', '107', '7.4.4', 'Study Committees', '108', '7.4.4.1', 'Data Safety Monitoring Board', '108', '7.4.4.2', 'Cardiovascular Adjudication Committee', '108', '7.4.5', 'Reporting of Adverse Events', '109', '7.4.5.1', 'Patient-Reported Outcome Data', '110', '7.4.5.2', 'Reporting of Serious Adverse Events', '110', '7.4.5.3', 'Reporting of Serious Adverse Events to', 'Regulatory Authorities and Investigators', '111', '7.4.5.4', 'Follow-up of Adverse Events', '111', '7.4.5.5', 'Follow-up of Serious Adverse Events by the', 'Investigator', '112', '7.4.6', 'Clinical Laboratory Evaluations', '112', '7.4.6.1', 'Laboratory Parameters', '112', '7.4.6.2', 'Mandatory Retesting of Laboratory', 'Abnormalities', '114', '7.4.7', 'Vital Signs, Physical Findings, and Other Safety', 'Assessments', '114', '7.4.7.1', 'Physical Examination', '114', '7.4.7.2', 'Vital Signs', '115', '7.4.7.3', 'Body Weight and Height', '115', '7.4.7.4', 'Cardiovascular Risk Assessment', '116', '7.4.7.5', 'Electrocardiogram', '116', '7.4.7.6', 'Evaluation of Chest X-ray', '116', '7.4.8', 'Safety Monitoring', '116', '7.4.9', 'Tuberculosis Risk Questionnaire', '117', '7.4.10', 'Management of Tuberculosis', '117', '7.5', 'Appropriateness of Measurements', '118', '8.', 'QUALITY CONTROL AND QUALITY ASSURANCE', '119', '8.1', 'Monitoring', '119', '8.2', 'Quality Assurance Audit', '122', 'Amendment 2: 06 March 2019', '14', 'Confidential']\n\n###\n\n", "completion": "END"}